Differential proteomic analysis of plasma-derived exosomes as diagnostic biomarkers for chronic HBV-related liver disease
Quick Facts
- Publication title: Differential proteomic analysis of plasma-derived exosomes as diagnostic biomarkers for chronic HBV-related liver disease
- Journal: SCI REP-UK
- Year: 2022
- DOI: 10.1038/s41598-022-13272-4
- PMID/PMCID: 36002595; PMC9402575
Research overview
Hepatitis B virus (HBV) infection is still a major public health problem worldwide. Thus, serum exosomes may be used as novel, liquid biopsy biomarkers to provide useful clinical information for the diagnosis of HBV-related liver diseases at different stages.
Key findings
Hepatitis B virus (HBV) infection is still a major public health problem worldwide.
We aimed to identify new, non-invasive biomarkers for the early diagnosis of chronic HBV-related diseases, reveal alterations in the progression of chronic hepatitis B (CHB), liver cirrhosis (LC), and hepatocellular carcinoma (HCC).
Here, exosomes were isolated and characterized through size exclusion chromatography and nanoparticle tracking analysis.
Profiles of differentially expressed proteins (DEPs) were analyzed through liquid chromatography-tandem mass spectrometry (LC-MS/MS), Gene Ontology, and Kyoto Encyclopedia of Genes and Genomes analyses.
Echo Biotech Role
Echo Biotech contributed EV isolation and purification, EV proteomics; the study also used or cited Exosupur®.
Related platforms: Exoomics®, Research Reagents & Tools
Related services and capabilities: Biofluid EV Isolation & Purification, EV Proteomics, Research Reagent / Product Supply
Related products or reagents: Exosupur® EV Isolation/Purification Kit
References
Original publication: Differential proteomic analysis of plasma-derived exosomes as diagnostic biomarkers for chronic HBV-related liver disease Scientific reports. 2022. DOI: 10.1038/s41598-022-13272-4. PMID/PMCID: 36002595; PMC9402575.